Piercarlo Sarzi-Puttini <br/><br/>
Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study 

<br/><br/><label>Subjects--Topical Terms: </label><br/>Computer science, information & general works